Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK5 | Q9Y337 | 3/20 | 0.62 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | BACE1 | P56817 | 1/20 | 0.53 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.52 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.52 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.52 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.52 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.52 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.52 |
| ▸ | APP | P05067 | 1/20 | 0.52 |
| ▸ | CTSS | P25774 | 2/20 | 0.51 |
| ▸ | CTSL | P07711 | 1/20 | 0.51 |
| ▸ | CTSB | P07858 | 1/20 | 0.51 |
| ▸ | CTSK | P43235 | 1/20 | 0.51 |
| ▸ | ACE | P12821 | 1/20 | 0.49 |
| ▸ | BCHE | P06276 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5217980 | 1.00 | KLK5 (0.62) | KLK5ATMBACE1PSEN1PSEN2 | |
| SCHEMBL5226929 | 0.90 | KLK5 (0.60) | KLK5ATMBACE1PSEN1PSEN2 | |
| SCHEMBL7309908 | 0.90 | KLK5 (0.65) | KLK5ATMBACE1PSEN1PSEN2 | |
| SCHEMBL30318987 | 0.89 | BACE1 (0.67) | KLK5ATMBACE1PSEN1PSEN2 | |
| SCHEMBL5404602 | 0.89 | KLK5 (0.59) | KLK5ATMBACE1PSEN1PSEN2 | |
| SCHEMBL5404605 | 0.89 | KLK5 (0.59) | KLK5ATMBACE1PSEN1PSEN2 | |
| SCHEMBL5392055 | 0.89 | KLK5 (0.64) | KLK5ATMBACE1PSEN1PSEN2 | |
| SCHEMBL5392060 | 0.89 | KLK5 (0.64) | KLK5ATMBACE1PSEN1PSEN2 | |
| SCHEMBL495921 | 0.89 | KLK5 (0.64) | KLK5ATMBACE1PSEN1PSEN2 | |
| SCHEMBL495922 | 0.89 | KLK5 (0.64) | KLK5ATMBACE1PSEN1PSEN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4153561-B1 | 9H-FLUOREN DERIVATES OR THEIR PHARMACEUTICALLY ACCEPTABLE SALTS | UNIV JAGIELLONSKI (PL) | 2026-04-29 | — | — | EP | disclosed |
| US-12492163-B2 | 9H-fluorene derivatives or their pharmaceutically acceptable salts | UNIWERSYTET JAGIELLONSKI (PL) | 2025-12-09 | — | — | US | disclosed |
| US-20230117233-A1 | NOVEL 9H-FLUORENE DERIVATIVES OR THEIR PHARMACEUTICALLY ACCEPTABLE SALTS | UNIWERSYTET JAGIELLONSKI (PL) | 2023-04-20 | — | — | US | disclosed |
| EP-4153561-A2 | 9H-FLUOREN DERIVATES OR THEIR PHARMACEUTICALLY ACCEPTABLE SALTS | UNIWERSYTET JAGIELLONSKI (PL) | 2023-03-29 | — | — | EP | disclosed |
| EP-1567488-B1 | HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | GLAXO GROUP LTD (GB) | 2007-02-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230117233-A1 | NOVEL 9H-FLUORENE DERIVATIVES OR THEIR PHARMACEUTICALLY ACCEPTABLE SALTS | BACE1, BACE2, APP | KLK5 3076/4885ATM 3819/4885BACE1 1/4885 |
| US-12492163-B2 | 9H-fluorene derivatives or their pharmaceutically acceptable salts | BACE1, BACE2, APP | KLK5 3203/4885ATM 3722/4885BACE1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.